Publication | Open Access

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

Metabolic SyndromeHypertensionRenal FunctionRenal DiseaseCardiovascular DiseaseMedicineKidney FailureDiabetesChronic Kidney DiseaseDiabetic Kidney DiseaseMajor Adverse KidneyDapa-ckd TrialPharmacologyAtherosclerosisCardiovascular Events